TITLE

Pharma IQ Test

PUB. DATE
November 2010
SOURCE
Pharmaceutical Representative;Nov2010, Vol. 40 Issue 11, p34
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A quiz concerning various pharmaceutical companies and its drug development is presented.
ACCESSION #
55433865

 

Related Articles

  • Further Reading.  // PharmaWatch: Monthly Review;Jan2009, Vol. 8 Issue 1, p40 

    The article lists several books related to pharmaceutical industry including "Phamaceutical Company Outlook to 2013," "Divestment Strategies: Pharma is divesting in order to grow," an "Forecast Insight: Antithrombotics - Market growth dependent on new agents."

  • Drugwatch.  // Formulary;Feb2003, Vol. 38 Issue 2, p116 

    Reports on developments in the pharmaceutical industry in the U.S. as of February 2003. New drugs; New indication, formulations and combinations.

  • Grid Computing Rescues Resources. Keating, Sean // Drug Discovery & Development;May2003, Vol. 6 Issue 5, p27 

    Focuses on the application of grid computing in drug development and pharmaceutical industry. Unification of sparse computing resources that otherwise go unused; Description of the grid computing projects of United Devices Inc. and Avaki Corp.

  • Expediting the formulation development process with the aid of automated dissolution in analytical research and development. Sadowitz, Jon P. // Journal of Automated Methods & Management in Chemistry;Nov2001, Vol. 23 Issue 6, p173 

    Focuses on the development of drugs in the generic pharmaceutical industry. Validation of the automated methodology; Details on the life cycle of the product; Categorization of the product.

  • Take My T Cells, Please. Peters, Rita C. // Drug Discovery & Development;Mar2011, Vol. 14 Issue 3, p6 

    An introduction to the journal is presented in which the editor discusses articles published within the issue including one by Ted Agres on the need for communication and education in the pharmaceutical industry, one by Catherine Shaffer on drug advancement and its effect on patient care, and...

  • Outcomes Based Access: Raising the Bar. Balekdjian, David; Russo, Michael // Pharmaceutical Executive;Nov2002, Vol. 22 Issue 10, p62 

    Explains the development of outcomes-based access in formulary submissions, its objectives and administration and how it is likely to affect pharmaceutical companies. Need to demonstrate that new therapies produce similar or better patient outcomes compared with existing products, while...

  • Beyond the Blockbuster. Franco, Robert J.; Kaitin, Kenneth I. // Pharmaceutical Executive;Nov2002, Vol. 22 Issue 10, p74 

    Focuses on the blockbuster product development in the pharmaceutical industry. Demonstration that product development experiences of medium-size drug companies carry important implications for larger companies; Need to generate a higher degree of cooperation with the competition.

  • The Drug Drought Primary Causes, Promising Solutions. Bernard, Stan // Pharmaceutical Executive;Nov2002 Supplement, Vol. 22, p6 

    Discusses the drug development problem of the pharmaceutical industry in the U.S. Decline in the number of approved compounds; Research and development causes of pharma's drought; Ways to alleviate the drug development problem of the industry.

  • Product UPDATE.  // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p28 

    Presents updates of several products from the pharmaceutical industry in the U.S. Details on the market for rosuvastatin from AstraZeneca; Approval of the anti-epileptic Trileptal drug from Novartis by the U.S. Food and Drug Administration; Submission of a series of applications by Wyeth for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics